Abstract
OBJECTIVE: In order to provide an overview of current knowledge, the literature was systematically examined for clinical studies, which evaluate the safety and effectiveness of bosentan in pediatric pulmonary arterial hypertension (PAH). SOURCES: 3 databases (MEDLINE, EMBASE and BIOSIS) were searched for the period January 2000 – October 2007 using the key words “pulmonary arterial hypertension”, “bosentan”, and “pediatric patients/children”. RESULTS: Of 165 identified publications, 21 clinical studies were selected: 1 interventional prospective, 6 observational prospective, 5 observational retrospective, and 9 case reports/case series. In the absence of controlled trials, these 21 studies represent the current evidence on the effectiveness and safety of bosentan in the treatment of pediatric PAH. Bosentan appears to improve long-term functional status and hemodynamics in children with PAH but improvement in exercise capacity is not consistently demonstrated. Promising results are reported for the combination of bosentan with other PAHspecific treatments although guidelines for instituting combination therapy have not been defined. Overall, no safety concern is raised by these studies; adverse events, including liver enzyme elevations, appear to be less frequent than reported in the adult PAH clinical trials. CONCLUSION: Recent experience, although uncontrolled, suggests that bosentan is a well-tolerated and effective therapy for pediatric PAH.
Keywords: Bosentan, endothelin, endothelin receptors, pulmonary arterial hypertension, pediatrics
Current Vascular Pharmacology
Title: Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
Volume: 7 Issue: 2
Author(s): Maurice Beghetti
Affiliation:
Keywords: Bosentan, endothelin, endothelin receptors, pulmonary arterial hypertension, pediatrics
Abstract: OBJECTIVE: In order to provide an overview of current knowledge, the literature was systematically examined for clinical studies, which evaluate the safety and effectiveness of bosentan in pediatric pulmonary arterial hypertension (PAH). SOURCES: 3 databases (MEDLINE, EMBASE and BIOSIS) were searched for the period January 2000 – October 2007 using the key words “pulmonary arterial hypertension”, “bosentan”, and “pediatric patients/children”. RESULTS: Of 165 identified publications, 21 clinical studies were selected: 1 interventional prospective, 6 observational prospective, 5 observational retrospective, and 9 case reports/case series. In the absence of controlled trials, these 21 studies represent the current evidence on the effectiveness and safety of bosentan in the treatment of pediatric PAH. Bosentan appears to improve long-term functional status and hemodynamics in children with PAH but improvement in exercise capacity is not consistently demonstrated. Promising results are reported for the combination of bosentan with other PAHspecific treatments although guidelines for instituting combination therapy have not been defined. Overall, no safety concern is raised by these studies; adverse events, including liver enzyme elevations, appear to be less frequent than reported in the adult PAH clinical trials. CONCLUSION: Recent experience, although uncontrolled, suggests that bosentan is a well-tolerated and effective therapy for pediatric PAH.
Export Options
About this article
Cite this article as:
Beghetti Maurice, Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension, Current Vascular Pharmacology 2009; 7 (2) . https://dx.doi.org/10.2174/157016109787455653
DOI https://dx.doi.org/10.2174/157016109787455653 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenomics of Essential Hypertension: Are We Going the Right Way?
Cardiovascular & Hematological Agents in Medicinal Chemistry Depression and Medication Adherence in Patients on Hemodialysis
Current Hypertension Reviews Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future
Current Pharmaceutical Design BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Cellular Balance, Genes,and the Huang Ti Nei Ching Su Wen
Current Neurovascular Research Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review
Current Medicinal Chemistry Hypercoagulability and Nephrotic Syndrome
Current Vascular Pharmacology Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Oligonucleotide-based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs
Current Drug Targets Lipid Mediator Profiling in Pulmonary Disease
Current Pharmaceutical Biotechnology Role of Nitric Oxide and Mitochondrial Nitric Oxide Synthase in Energy Adaptive Responses
Current Cardiology Reviews Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry Active Targeted Drug Delivery for Microbes Using Nano-Carriers
Current Topics in Medicinal Chemistry Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
Current Hypertension Reviews Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Effect of Ouabain on the Immune System
Current Hypertension Reviews